Session 11 - IC-OS 2021 and Beyond

Dr. Arnold is a native New Yorker and studied General and Interventional Cardiology at the Cleveland Clinic Foundation in Cleveland, Ohio, USA. As a cancer survivor herself, she is passionate about Cardio-Oncology and presently is an Associate Professor of Medicine at Florida State University, the Founding Director of the Cardio-Oncology program and Transitional Clinic for childhood cancer survivors at Lee Health in Florida, a Board of Director member and Chair of the Education Committee for ICOS, and the past chair of the Advocacy working group for the Cardio-Oncology section of the American College of Cardiology. She is interested in disparities in healthcare especially as it relates to Cardio-Oncology.

Dr. Anju Nohria is the Director of the Cardio-Oncology Program at Dana-Farber/Brigham and Women’s Cancer Center and a cardiovascular specialist in heart failure and transplantation at Brigham and Women’s Hospital (BWH). In addition, she is an Assistant Professor of Medicine at Harvard Medical School (HMS). Dr. Nohria received her medical degree from HMS. She completed an internal medicine residency and was a chief resident at Yale-New Haven Hospital. She then completed both a cardiovascular medicine fellowship and a heart failure and transplantation fellowship at BWH. She is board certified in cardiovascular disease and heart failure and transplantation. Dr. Nohria’s clinical interests include cardio-oncology and heart failure and transplantation. The author of approximately 100 peer-reviewed publications, she currently researches how to evaluate, prevent and treat cardiovascular complications that can arise as a result of cancer therapy.

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Lauren A. Baldassarre, MD is Associate Professor of Cardiovascular Medicine and Radiology & Biomedical Imaging at Yale School of Medicine in New Haven, CT. She is the Director of the Yale Smilow Cancer Center Cardio-Oncology Program and the Cardiology Director of Cardiac MR/CT for Yale New Haven Hospital. She is also the Program Director for the newly established Yale Cardio-Oncology Advanced Fellowship Program. Dr. Baldassarre is a member of the American College of Cardiology Cardio-Oncology Section Leadership Council and is the Chair of the International Cardio-Oncology Society Imaging Work Group. She is the Chair of the Society for Cardiovascular Magnetic Resonance Cardio-Oncology Special Interest Group and is a member of the Society of Cardiovascular Computed Tomography Cardio-Oncology Writing Group. Her clinical and research interests include the use of advanced multimodality cardiac imaging for the detection, management, and prevention of cardiotoxicity from cancer therapeutics.

Dr. Roohi Ismail-Khan is a medical oncologist and provides care for cancer patients in the Cardio-Oncology and Survivorship Programs. She has an interest in Women’s Health and has served more than 10 years taking care of Breast Cancer patients and has now joined the gynecologic oncology program at Moffitt Cancer Center. Recently, she has concentrated her clinical efforts to help patients with cancer who also have high risk cardiovascular disease. She works closely with Cardiology in helping patients balance the treatment for their cancer and their co-existing CV disease. She serves as the co-director of the new Cardio-Oncology Program. She completed her Internal Medicine Residency at the University of South Florida and served as chief resident in her final year. She completed her Medical Oncology Fellowship at the H. Lee Moffitt Cancer Center and completed her MS in Clinical Research during her fellowship. Her clinical focus and research is focused upon identifying high risk patient cohorts and minimizing cardiovascular side effects in patients receiving cardio-toxic therapy. Dr. Ismail-Khan is also an active teacher and mentor for USF medical students, Internal Medical residents, and Medical Oncology Fellows.

Dr. Stephen Casselli is an executive director at International Cardio-Oncology Society.

Dr. Vijay Rao is the Director of CardioOncology, Heart Failure, and Anticoagulation at Franciscan Health, Indianapolis, Indiana. He graduated with a dual degree MD and PhD from the Medical University of South Carolina followed by Internal Medicine training at Duke University Medical Center. He then completed Cardiology fellowship at the University of California, San Francisco followed by a dedicated additional year in echocardiography serving as the Chief Fellow. He is the governor-elect for the Indiana Chapter of the American College of Cardiology. Under his leadership, the Franciscan CardioOncology team was awarded an Associate of Community Cancer Centers National Innovator Award in 2020 for “Nurse Navigation as a Model for Developing an CardioOncology Program.” Dr. Rao was also the first author on a recent State of the Art Review published in Journal of American College of Cardiology June 2021 issue titled “Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents.” He also serves as the Chair of the ICOS Center of Excellence Committee and is an active member of the ICOS Education Committee.